Introduction to Standard Of Care Second Line And Future Therapies For Gej And Esophageal Adenocarcinoma
Let's dive into the details surrounding Standard Of Care Second Line And Future Therapies For Gej And Esophageal Adenocarcinoma. Drs Samuel Klempner and Zev Wainberg discuss
Standard Of Care Second Line And Future Therapies For Gej And Esophageal Adenocarcinoma Comprehensive Overview
Manish A. Shah, MD, provides insight on when to recommend Manish A. Shah, MD, discusses how he would characterize the 54-year-old man's response to chemotherapy for his stage 4 ... This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
Dr. Daniel Catenacci, gastrointestinal
Summary & Highlights for Standard Of Care Second Line And Future Therapies For Gej And Esophageal Adenocarcinoma
- When metastatic
- Chair Ronan J. Kelly, MD, MBA, and Siva Raja, MD, PhD, FACS, discuss
- This video is part of the HMP Education content archive and may include previously accredited educational material. While this ...
- Co-Chairs Jaffer A. Ajani, MD, and Ian Chau, MD, FRCP, discuss GI
- Join the DDF Staff and GI Oncologist, Dr. Daniel Catenacci, for a lunchtime presentation on Immunotherapy. Dr. Daniel Catenacci ...
That wraps up our extensive overview of Standard Of Care Second Line And Future Therapies For Gej And Esophageal Adenocarcinoma.
